

25th March, 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA

ISIN: INE0XJ501010

Subject: Outcome of the Board Meeting held on 25th March, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Meeting of Board of Directors of the Company held on Wednesday, 25th March, 2026 at 10.30 a.m. and concluded at 12.30 p.m.

The Meeting was duly convened and its outcome is as below:

- I. Based on the recommendation of Nomination and Remuneration Committee, Board appointed Mr. Rohit Prakash Srivastava (DIN: 01432112) as Additional Director of the company who shall hold office till the date of ensuing Extra Ordinary General Meeting.

Board Further appointed him as Whole Time Director- Finance of the Company for a period of 5 (five) consecutive years starting from 25th March, 2026, subject to approval of shareholders in the ensuing Extra Ordinary General Meeting. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are mentioned below as Annexure-1.

- II. Considered and Approved Material Related Party Transactions with following related parties, in the ordinary course of business and on arm's length basis, pursuant to Section 188 of the Companies Act, 2013 and applicable regulation of SEBI LODR 2015, subject to approval of shareholders in ensuing Extra Ordinary General Meeting:

1. PCD Diagnostics LLP, Subsidiary LLP
2. Pratham MRI and CT Scan Centre, Subsidiary Firm
3. Primacare Healthcare LLP, Subsidiary LLP
4. Invicta Medical LLP, Subsidiary LLP
5. Primacare Diagnostic LLP, Subsidiary LLP
6. Mscribeit Infotech LLP, Associate LLP
7. Porteus Medical LLP, Subsidiary LLP
8. Invicta Diagnostic Lifecare LLP, Subsidiary LLP
9. Invicta Diagnostic Healthplus LLP, Subsidiary LLP
10. Shegaon Diagnostic LLP, Subsidiary LLP

- III. Considered and Approved Related Party Transactions with following related parties, in the ordinary course of business and on arm's length basis, pursuant to Section 188 of the Companies Act, 2013 and applicable regulation of SEBI LODR 2015, subject to approval of shareholders in ensuing Extra Ordinary General Meeting:

1. Ms. Komal Sanket Jain
2. Ms. Garima Naredi
3. Ms. Aditi Jayesh Jain
4. Ms. Payal Kunal Jain

IV. On the recommendation of the Audit Committee, the Board of the Company at their Meeting held on i.e. on 25th March, 2026, has approved for Change, Deviation and Variation in the Objects and terms of Utilisation of the Initial Public Offering (“IPO”) Proceeds and extension of time limit for utilisation of the IPO Proceeds in the following manner in order to take benefit of:

1. Establishing diagnostic centres at most promising locations
2. Choosing medical equipment which are most suitable and technologically advanced equipment
3. Brand value and goodwill of local medical professionals, operational flexibility, and optimize capital deployment for scaling the diagnostic network

Sr. No.	Original Object	Total Amount Raised (Rs. in Lakhs)	Amount Reallocated	Details of Variation / Deviation	Amount reallocated for Object NO. 3 (Rs. in Lakhs)	Revised Timeline for Utilization
1	Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra	2,111.33	1351.33*	Instead of establishing five diagnostic centres as originally proposed, the Company proposes to commence atleast five diagnostic centres in Maharashtra directly or through subsidiary entities including Diagnostic Centre at Object No. 3. Further, there is change in brands and modalities of machinery proposed to be installed. Details of New Object, variation and deviation is given in explanatory statement.	760.00 (to be utilised for New Object No. 3)	Up to March 2027
2	General Corporate Purposes	407.46	422.56**	Amount of Rs. 15.10 lakhs remained after payment of Issue related Expenses is reallocated towards expenses for General Corporate Purpose.	NIL	Up to March 2027
3	New Object: Nashik Centre - Acquisition of up to 95% stake	—	760.00	New Object proposed to be funded out of revised unutilized		Up to March 2027

	in Vinchurkar Diagnostics Private Limited (VDPL)			amount from Object No. 1.		
	Total	2518.79	2533.89			

* Rs. 1351.33 Lakh includes amount of Rs. 227.79 Lakhs till date utilised for purchase of machinery.

** Includes General Corporate Purpose expenses paid till date of Rs. 238 Lakhs.

The Board of the Company at their Meeting held on i.e. on 25th March, 2026, has approved, subject to approval of shareholders in ensuing Extra Ordinary General Meeting, for variation in the manner of implementation of the aforesaid object, without exceeding the overall allocation of Rs. 2,111.33 Lakhs, to provide the Company with operational flexibility, including:

- a. Establishment of atleast three diagnostic centres at suitable locations in Pune, Akola and Mumbai Metropolitan region (MMR) and the fourth diagnostic centre shall be opened in any other city within the state of Maharashtra with similar demography and business potential basis, instead of being restricted only to the locations indicated in the Prospectus;
 - b. Establishment and operation of such diagnostic centres either directly by the Company or through subsidiary entities, in which the Company shall have a majority stake;
 - c. Flexibility in procurement of medical equipment of globally recognised original equipment manufacturers including but not limited to Siemens Healthineers, GE Healthcare, Philips Healthcare, Fujifilm Healthcare or other equivalent OEMs;
 - d. Procurement of upgraded, advanced or technologically superior equipment, including purchase of 3T MRIs and Cardiac CT (64 slice CT /128 slice CT) in place of a 16 slice CT, including variation in cost up to $\pm 25\%$ of the indicative cost disclosed in the Prospectus;
 - e. Inclusion of PET-CT system in place of a CT Scan system at centres where a demand is perceived and it makes more commercial sense; and
 - f. Utilisation of up to Rs. 760.00 lakhs out of the unutilised amount under Object No. 1 towards acquisition of up to 95% equity stake in Vinchurkar Diagnostics Private Limited (Nashik Centre);
 - g. Amount (Including interest accumulated) if any remained, after setting up of above 5 diagnostic centres (including the acquisition of Vinchurkar Diagnostics Private Limited) is to be used for setting up of additional diagnostic centres in Maharashtra with similar modalities under company or through subsidiary entities.
- V. Approved Notice calling Extra Ordinary General Meeting of the shareholders of the company to be held on Friday, April 17, 2026 at 11.00 AM(IST) through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM') facility.

Thanking you,

You are requested to take the same on record.

Yours Faithfully,

For Invicta Diagnostic Limited

Sanket Vinod Jain
Chairman and Non-Executive Director
DIN: 08299039
Place: Mumbai

Annexure-1

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No.	Disclosure requirements	Details
1	Reason for Change viz appointment, Resignation, removal, death or otherwise	Appointment of Mr. Rohit Prakash Srivastava (DIN: 01432112) as an Additional Director of the Company with effect from 25 th March, 2026. Board Further appointed him as Whole Time Director- Finance
2	Date of Appointment/ re-appointment/ cessation (as applicable) & terms of appointment/ re-appointment.	Date of Appointment - Wednesday, 25th March, 2026 Terms of appointment- <ul style="list-style-type: none"> • Tenure as an Additional Director – Till Ensuing Extra Ordinary General Meeting. • Tenure as Whole-Time Director (Finance) – [5] years with effect from March 25, 2026 subject of approval of shareholders in ensuing Extra Ordinary General meeting Remuneration - Rs. 7.20 Lakh per annum Perquisites and allowances - Whole-Time Director (Finance) of the Company is entitled to draw any perquisites from the Company as provided in Section 197 and Section II (A) of Part II of Schedule V to the Companies Act, 2013 inclusive of above remuneration.
3	Brief Profile (In case of Appointment)	Mr. Rohit Prakash Srivastava has done MBA in Finance and Marketing. He has over 19 years of diverse experience across industries including Investment Banking, Education, Wealth Management, and Healthcare.
4	Disclosure of relationship between directors (In case of Appointment)	Ms. Konica Srivastava, Manager of the company is his Spouse.
5	Declaration	In accordance with the SEBI instructions to stock exchanges dated June 14, 2018, we confirm that Mr. Rohit Prakash Srivastava is not debarred from holding the office of Directors of the company by virtue of the SEBI order or any other such authority
6	Affirmation	This is to affirm that Mr. Rohit Prakash Srivastava is not disqualified from holding the office of director pursuant to section 164 of the Companies Act 2013
7	Shareholding	13,91,488 Equity Shares of Rs. 10 each constituting 11.07%

For Invicta Diagnostic Limited

Sanket Vinod Jain
Chairman and Non-Executive Director
DIN: 08299039
Place: Mumbai

Annexure-2

Proposed Revised Object clause is detailed below

Sr. No.	Object	Amount to be funded from Net Proceeds (Rs. in Lakhs)	Amount to be deployed from the Net Proceeds in Fiscal 2026 (Rs. in Lakhs)	Amount to be deployed from the Net Proceeds in Fiscal 2027 (Rs. in Lakhs)
1	Start at least four diagnostic centres in Maharashtra directly or through subsidiary entities (wherein the Company shall hold minimum 51% stake)	1351.33	500.00	851.33
2	Acquisition of Vinchurkar Diagnostics Private Limited	760.00	0.00	760.00
3	General Corporate Purposes	*422.56	350.00	72.56
	Total	2533.89	850.00	1683.89

* Amount of Rs. 15.10 lakhs remained after payment of Issue related Expenses is reallocated for General Corporate Purpose

Establishment of Five Diagnostic Centres through Subsidiary entity including acquisition of VDPL & Company's Stake	Number of new Diagnostic Centres	Location	Medical equipment	Expected deployment from IPO proceeds equipment cost (₹ in lakhs)
Porteus Medical LLP (52%)	1	Pune	CT & MRI	416.00
Shegaon Diagnostic LLP (51%)	1	Shegaon (Akola)	CT	43.50
Primacare Diagnostic LLP (90%)	1	Mumbai	PET CT	335.00
Vinchurkar Diagnostics Private Limited (acquisition of Upto 95%)	1	Nashik	CT & MRI	760.00
New Diagnostic Centre/s to be decided by Board in any other city within the state of Maharashtra with similar demography and business potential basis	As may be decided by the Board	Within Maharashtra	As may be decided by Board	556.83
Total				2111.33

For Invicta Diagnostic Limited

Sanket Vinod Jain
Chairman and Non-Executive Director
DIN: 08299039
Place: Mumbai

Annexure-3

The disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, read with SEBI Master Circulars dated November 11, 2024 and December 31, 2024, in relation to the acquisition of Vinchurkar Diagnostics Private Limited, were already submitted as part of the outcome of the Board Meeting held on January 05, 2026.

However, in the interest of enhanced corporate governance and compliance, the Company is resubmitting the aforesaid disclosures

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc	<p>Name of the Company to be acquired: Vinchurkar Diagnostics Private Limited</p> <p>Date of Incorporation: 12/05/1993</p> <p>Country of incorporation: H. No. 1372/A, Vinchurkar Banglow Behind SBI, Old Agra Road, Nashik, Maharashtra, India, 422002</p> <p>Brief Profile: Vinchurkar Diagnostics Private Limited is a long-standing diagnostic company in Nashik, India, established in 1993, offering various CT, MRI and Diagnostic tests known for its 24/7 service. It is the first Diagnostic centre who Started Pvt CT & Mammography centre in Nasik in June 1995, MRI in 1999, Superconducting MRI in 2004 etc.</p> <p>Turnover for FY 2024-25: Rs. 445.44 Lakhs</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3	Industry to which the entity being incorporated belongs	Diagnostic Services (Healthcare Service in radiology and pathology solutions)
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for incorporation / acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>The company is engaged, <i>inter alia</i>, in the business of Diagnostic Services (Healthcare Service in radiology and pathology solutions)</p> <p>This acquisition will expand the business activities of the company in Nashik city.</p>
5	Brief details of any governmental or regulatory approvals required for the incorporation / acquisition	None / Not Applicable

6	Indicative time period for completion of the acquisition / Incorporation	Upto 12 Months								
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash								
8	Cost of subscription/price at which the shares are subscribed / acquired	Proposed cash consideration of Rs. 760 Lakhs								
9	Percentage of shareholding/control by the listed entity and/or number of shares allotted	Proposed acquisition of upto 95% shareholding of Vinchurkar Diagnostics Private Limited in two Tranches i.e. 1 st Tranche 51% by June 30, 2026, 2 nd Tranche of Maximum 44% within 9 months of first tranche. Total cash consideration of Rs. 760 Lakhs								
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Brief Background and Significant Information:</p> <p>Vinchurkar Diagnostics Private Limited is a long-standing diagnostic company in Nashik, India, established in 1993, offering various CT, MRI and Diagnostic tests known for its 24/7 service. It is the first Diagnostic centre who Started Pvt CT & Mammography centre in Nasik in June 1995, MRI in 1999, Superconducting MRI in 2004 etc.</p> <p>Country: India</p> <table border="1"> <thead> <tr> <th></th> <th>Turnover (Rs. in lakhs)</th> </tr> </thead> <tbody> <tr> <td>2024-25</td> <td>445.44</td> </tr> <tr> <td>2023-24</td> <td>444.53</td> </tr> <tr> <td>2022-23</td> <td>410.90</td> </tr> </tbody> </table>		Turnover (Rs. in lakhs)	2024-25	445.44	2023-24	444.53	2022-23	410.90
	Turnover (Rs. in lakhs)									
2024-25	445.44									
2023-24	444.53									
2022-23	410.90									

For Invicta Diagnostic Limited

Sanket Vinod Jain
 Chairman and Non-Executive Director
 DIN: 08299039
 Place: Mumbai